WHC is still in active development. Read this to understand our approach.
depiction of HPHUVLMMVZITSG-UHFFFAOYSA-N.svg
isomerdesign

Etiracetam

Verificar en isomerdesign

isomerdesign

Levetiracetam

Verificar en isomerdesign

pubchem

Levetiracetam

Verificar en pubchem

drugmap

Levetiracetam

Verificar en drugmap

wiki

Etiracetam

Verificar en wiki

wiki

Levetiracetam

Verificar en wiki

Data

InChI: InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)

Sinónimos: LEVETIRACETAM [MI],(S)-2-(2-Oxo-1-pyrrolidinyl)butyramide,SR-01000759400,LEVETIRACETAM ACTAVIS GROUP, Levetiracetam In Sodium Chloride,ucb L059,(S)-Levetiracetam,Levetiracetamum,AB00639945-06,LEVETIRACETAM [VANDF],AC-1479,AKOS015841981,(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide, UCB-L 059,UCB 22059, ucb L060,SR-01000759400-4,Levetiracetam [USAN:USP:INN:BAN],LEVETIRACETAM [ORANGE BOOK],NCGC00186028-01, Levetiracetamum,MLS006010215,(2S)-2-(2-oxopyrrolidin-1-yl)butanamide;Levetiracetam,AM20070676,LEVETIRACETAM [USP-RS],BCP11856, Ucb L060,Levetiracetam actavis,E keppra (TN),MLS001424069,N03AX14, Etiracetam, S-isomer,HSDB 7528,HY-B0106,(S)-2-(2-oxopyrrolidin-1-yl)butyramide, UCB-22059,NSC760119,Levetiracetam- Bio-X,SCHEMBL118843, Levetriacetam, Levetiracetamum [INN-Latin],Keppra XR,matever,Levroxa,BL164623,Levetiracetam [INN],HMS2089L20,(S)-2-(2-Oxopyrrolidin-1-yl)butanamide,Levitiracetam, Pharmaceutical Secondary Standard; Certified Reference Material,UNII-44YRR34555,Levesam 500, Keppra,Levetiracetam,UCB-22059,(-)-(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide (2S)-2-(2-Oxo-pyrrolidin-1-yl)butanamide,E Keppra,GTPL6826,AB00639945_08,Elepsia XR,Levetiracetam, >=98% (HPLC),HMS2051D07,Z1255435426,LEVETIRACETAM [MART.],HMS3713P16,(-)-(S)-.ALPHA.-ETHYL-2-OXO-1-PYRROLIDINEACETAMIDE,LEVETIRACETAM [EMA EPAR],D00709,Pharmakon1600-01502265,1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (S)-, (-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide,AB00639945_07,NSC-760119, (S)-2-(2-Oxopyrrolidin-1-yl)butanamide,MFCD03265610,(2S)-2-(2-oxopyrrolidin-1-yl)butanamide,Levetiracetam, United States Pharmacopeia (USP) Reference Standard,ACT02712,Levetiracetam (JAN/USP/INN),Levetiracetamum [INN-Latin],MLS000759403,LEVETIRACETAM RATIOPHARM,NC00178,NSC 760119, SIB-S1,Levetiracetam accord,Etiracetam levo-isomer,L-059,LEVETIRACETAM [HSDB], 44YRR34555,(S)-2-(2-OXO-PYRROLIDIN-1-YL)-BUTYRAMIDE, Levetiractam,LEVETIRACETAM [EP IMPURITY], Etiracetam levo-isomer,1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-,STL388027,KS-1176,SDCCGSBI-0633760.P001,Tox21_500835,Levetiracetam In Sodium Chloride,Levetiracetam, European Pharmacopoeia (EP) Reference Standard,Elepsia, (2S)-2-(2-oxopyrrolidin-1-yl)butanamide,Levetiracetam, analytical standard,DB01202,SW197558-3,44YRR34555,CCG-100928, Levetiracetam [INN],Levetiracetam hospira,767L282, Keppra XR,LEVETIRACETAM [USP IMPURITY], 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-,,(s)-2-(2-oxopyrrolidin-1-yl) butyramide,Levetiracetam solution,102767-28-2,DTXSID9023207,Levipil,Levetiracetame,Leviteracetam,ZINC1547851,Keppra (TN),BIDD:GT0242,LP00835,(2S)-(2-Oxopyrrolidin-1-yl)butyramide, Keppra (TN),HMS3884O11, Levroxa,LEVETIRACETAM [EP MONOGRAPH],CHEMBL1286,LEVETIRACETAM [USAN],s1356,SMR000466303,NCGC00186028-13,Levetiracetam sun,CS-1854, (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide, 1-Pyrrolidineacetamide, alpha-ethyl-2-oxo-, (alphaS)-,LEVETIRACETAM [JAN],Keppra,BDBM50422542,UCB-L 059,ALBB-027275,UCB-L059,HMS3262H11,NCGC00261520-01,Torleva,LEVETIRACETAM [USP MONOGRAPH], ucb L059, Keppra, L-059, Leviteracetam,SIB-S1,Levetiracetam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,C07841, CHEBI:6437, UCB-L059,AGB-101, Keppra, Keppra XR),Levetiracetam,(S)-(-)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide,(-)-(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide,1-Pyrrolidineacetamide, .alpha.-ethyl-2-oxo-, (.alpha.S)-, Spritam,Levetiracetam 1.0 mg/ml in Methanol,EN300-244575,L0234, Torleva,Levetiracetam teva,A800616,Etiracetam, UNII-44YRR34555,CHEBI:6437,Q-201292,SR-01000759400-5,HMS2235I18,Spritam,LEVETIRACETAM [WHO-DD]

Estimated data

Solubilidad: -0.449 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 47.8% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.